Laura Jones reports findings from the 2015 European Cancer Congress, including impressive results for nivolumab and cabozantinib in renal cell carcinoma, practice-changing data for everolimus and a new radionuclide in neuroendocrine tumors, pivotal findings in lung cancer and bladder cancer for atezolizumab, and more.

свернуть